What is achondroplasia?

Achondroplasia is the most common form of skeletal dysplasia (a condition affecting bone growth) and is the most common cause of disproportionate short stature. The classic features include short stature with disproportionately short upper arms and thighs, large head with prominent forehead and flattened nasal bridge, short fingers, and (in many people) some specific spinal and other complications that develop over time.

The genetics. Achondroplasia is caused by a specific mutation in the FGFR3 gene (most commonly the same single change in nearly all cases). This mutation makes the FGFR3 protein overactive, which slows the growth of cartilage at growth plates (the parts of bones where lengthening happens during childhood). Most cases of achondroplasia arise from a new mutation rather than being inherited from a parent.

The associated medical considerations. Children and adults with achondroplasia have higher rates of certain medical issues that benefit from structured monitoring and care: narrowing where the spinal cord exits the skull (foramen magnum stenosis, particularly important to identify in infancy), middle ear issues and hearing problems, sleep apnea, spinal stenosis (often in adulthood), and dental crowding. Comprehensive care addresses these proactively.

The new disease-modifying therapy.

Vosoritide is a daily subcutaneous injection that signals through a different pathway (C-natriuretic peptide receptor) to counteract the overactive FGFR3 signalling. It increases growth velocity in children with achondroplasia and is associated with improved body proportions. Vosoritide is approved for children with achondroplasia from 4 months of age to growth plate closure. Real-world evidence is accumulating on long-term growth outcomes, body proportions, bone outcomes, and complications.

The emerging direction.

Follow-on CNP analogue medicines (potentially with longer dosing intervals or oral formulations) are in late-stage trials. FGFR3-targeted medicines (small molecules that block FGFR3 signalling, monoclonal antibodies targeting FGFR3) are reading out and represent a different mechanism for slowing the underlying biological driver. Whether disease-modifying therapy in childhood reduces the long-term complications of achondroscopia (spinal stenosis, foramen magnum issues) is one of the most important questions for the next decade of follow-up data.

The surgical considerations. Some children and adults with achondroplasia benefit from specific surgical procedures: foramen magnum decompression in infants with significant compression, spinal decompression for spinal stenosis, and (controversially) limb-lengthening surgery in selected adolescents and adults. Limb-lengthening involves long, demanding procedures and is a deeply individual choice that benefits from open conversation with experienced specialists and with the disability community.

What to expect. Achondroplasia is a lifelong condition with specific medical considerations that benefit from structured comprehensive care, ideally at a skeletal dysplasia centre of excellence. The disease-modifying therapy options in childhood are a major change from the previous era, and follow-up data over the next 10 to 20 years will clarify their long-term impact on growth, body proportions, and complications. For adults with achondroplasia, surveillance and proactive management of associated medical issues are the most important things modern care offers.